Evaluation Of Usefulness Of Ropinirole In The Treatment Of Post Covid Restless Leg Syndrome - A Homogenous Quasi-Experimental Feasibility Study

Background: Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a widely known, prolonged, multifactorial limb movement disorder wherein patients have an insatiable desire to move their legs. This is frequently associated with abnormal, non-painful sensations that begin at rest and improve with activity and pain may be the distressing symptom in a few. Ropinirole, a dopamine agonist, is a proven drug for this disease. Method(s): In this study of thirty-two post covid restless leg syndrome, selected by well-established criteria, a course of ropinirole 2 mg in the night was given for three weeks. The drug compliance was maintained more than 95% by telephonic interview. The pain scores (VAS 0- 10), Likert scores of satisfactions, were observed after three weeks and three months. Result(s): The scores significantly decreased after three weeks which maintained the same and an insignificant decrease after three months. The median score decreased from 7 to 3 (three weeks) to 2 in three months. The Likert satisfaction scores improved to 1.81 from three (p value= 0.00). There was improvement in scores from three weeks to three months. There were no side effects. Conclusion(s): In this single centre, quasi experimental study on the efficacy of ropinirole on post covid restless syndrome, we found the drug dosage of 2 mg in the night for three weeks is effective in the control of symptoms. The drug gives better satisfaction which prolonged to three months even if the drug is stopped in three weeks. There were no clinically significant side effects. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.

Current treatment options for feline infectious peritonitis in the UK

Until recently, feline infectious peritonitis was an invariably fatal disease that occurs when a ubiquitous enteric coronavirus mutates. This enables it to replicate effectively within macrophages, resulting in immune-mediated phlebitis and serositis. While our understanding of the aetiopathogenesis of feline infectious peritonitis remains unchanged, with the recent availability of legalised antiviral drugs, successful treatment is now a possibility, albeit at a cost. As we approach a new dawn of research into the diagnosis and treatment of this disease, this review summarises current therapeutic options. Please note, some protocols are still being optimised.